Jazz Pharmaceuticals Announces Executive and Board Changes

Ticker: JAZZ · Form: 8-K · Filed: Oct 28, 2025 · CIK: 1232524

Jazz Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type8-K
Filed DateOct 28, 2025
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-of-directors, executive-appointments

TL;DR

Jazz Pharma shakes up leadership and board - new execs and directors appointed.

AI Summary

Jazz Pharmaceuticals plc announced on October 23, 2025, changes in its executive team and board of directors. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel.

Why It Matters

Changes in leadership and board composition can signal shifts in company strategy, governance, and future direction.

Risk Assessment

Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and operations.

Key Players & Entities

FAQ

What specific roles have been affected by these changes?

The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', suggesting shifts in leadership positions.

When was the earliest event reported in this filing?

The date of the earliest event reported is October 23, 2025.

What is the company's Standard Industrial Classification (SIC) code?

The SIC code for Jazz Pharmaceuticals plc is 2834, which corresponds to Pharmaceutical Preparations.

Where is Jazz Pharmaceuticals plc incorporated?

Jazz Pharmaceuticals plc is incorporated in Ireland.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

Filing Stats: 699 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2025-10-28 16:15:33

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: October 28, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing